Cancer Causes & Control

, Volume 26, Issue 11, pp 1627–1642 | Cite as

Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden

  • Aaron J. KatzEmail author
  • Victoria M. Chia
  • Wilma M. Schoonen
  • Michael A. Kelsh
Original paper



Acute lymphoblastic leukemia (ALL) is a rare hematological malignancy. With the recent introduction of a classification system for hematopoietic and lymphoid neoplasms, more comprehensive assessment of ALL epidemiology is now possible. In this study, we describe recent international incidence of ALL and project the annual number of diagnoses to 2025. We also estimate relative survival and average potential years of life lost (AYLL) to assess the societal burden of ALL.


Age-specific incidence data for ALL from select cancer registries in different geographies were obtained from the International Agency for Research on Cancer’s Cancer Incidence in Five Continents Database. Country-specific age-standardized rates were calculated to allow for direct comparisons between countries. ALL-specific mortality and relative survival data were only available from the United States (US) National Cancer Institute’s Surveillance, Epidemiology, and End Results program; mortality rates were estimated for other countries.


The age-standardized incidence rate of ALL during 2003–2007 ranged from 1.08 to 2.12 per 100,000 person-years in selected countries. Incidence was generally higher in the Americas and Oceania and lower in Asia and Eastern Europe. In most countries, the incidence rate of ALL in children was approximately four times that in adults. Survival was particularly poor among adults. In selected countries, the estimated AYLL ranged from 30 to 48 years for all ages and from 23 to 39 years for adults.


Although a rare disease, ALL presents a significant public health burden given poor survival outcomes among adults, AYLL, and its importance as the most common pediatric cancer.


Acute lymphoblastic leukemia International Incidence Projections Survival Potential years of life lost 


Compliance with ethical standards

The manuscript does not contain clinical studies, patient data, or research involving human participants or animals.

Conflict of interest

A.J.K., V.M.C., and M.A.K. are employees of Amgen Inc. W.M.S. is an employee of Amgen Ltd.


  1. 1.
    Wartenberg D, Groves FD, Adelman AS (2008) Acute lymphoblastic leukemia: epidemiology and etiology. In: Estey EH, Faderl S, Kantarjian H (eds) Acute leukemias, 1st edn. Springer, Berlin, pp 77–93CrossRefGoogle Scholar
  2. 2.
    Groves FD, Linet MS, Devesa SS (1995) Patterns of occurrence of the leukaemias. Eur J Cancer 31a:941–949CrossRefPubMedGoogle Scholar
  3. 3.
    Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ et al (2012) Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol 30:1663–1669. doi: 10.1200/jco.2011.37.8018 PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC et al (2009) Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360:2730–2741. doi: 10.1056/NEJMoa0900386 PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM et al (2005) Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 106:3760–3767. doi: 10.1182/blood-2005-04-1623 CrossRefPubMedGoogle Scholar
  6. 6.
    Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E et al (2009) Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 27:911–918. doi: 10.1200/jco.2008.18.6916 CrossRefPubMedGoogle Scholar
  7. 7.
    Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S et al (2012) Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol 157:463–471. doi: 10.1111/j.1365-2141.2012.09095.x PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Thomas DA, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W et al (2010) Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 28:3880–3889. doi: 10.1200/jco.2009.26.9456 PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Oriol A, Vives S, Hernandez-Rivas JM, Tormo M, Heras I, Rivas C et al (2010) Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 95:589–596. doi: 10.3324/haematol.2009.014274 PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G et al (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109:944–950. doi: 10.1182/blood-2006-05-018192 CrossRefPubMedGoogle Scholar
  11. 11.
    Gökbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Huttmann A et al (2012) Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120:2032–2041. doi: 10.1182/blood-2011-12-399287 CrossRefPubMedGoogle Scholar
  12. 12.
    Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019–5032. doi: 10.1182/blood-2011-01-293050 PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    American Cancer Society (2011) Global cancer facts and figures, 2nd edn. American Cancer Society, AtlantaGoogle Scholar
  14. 14.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917. doi: 10.1002/ijc.25516 CrossRefPubMedGoogle Scholar
  15. 15.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi: 10.3322/caac.20107 CrossRefPubMedGoogle Scholar
  16. 16.
    Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM (2012) Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood 119:34–43. doi: 10.1182/blood-2011-04-347872 PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Dalmasso P, Pastore G, Zuccolo L, Maule MM, Pearce N, Merletti F et al (2005) Temporal trends in the incidence of childhood leukemia, lymphomas and solid tumors in north-west Italy, 1967–2001. A report of the Childhood Cancer Registry of Piedmont. Haematologica 90:1197–1204PubMedGoogle Scholar
  18. 18.
    Linabery AM, Ross JA (2008) Trends in childhood cancer incidence in the U.S. (1992–2004). Cancer 112:416–432. doi: 10.1002/cncr.23169 CrossRefPubMedGoogle Scholar
  19. 19.
    Parkin DM, Stiller CA, Draper GJ, Bieber CA (1988) The international incidence of childhood cancer. Int J Cancer 42:511–520CrossRefPubMedGoogle Scholar
  20. 20.
    Yamamoto JF, Goodman MT (2008) Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002. Cancer Causes Control 19:379–390. doi: 10.1007/s10552-007-9097-2 CrossRefPubMedGoogle Scholar
  21. 21.
    Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S et al (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164:536–545. doi: 10.1111/bjh.12659 PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Marcos-Gragera R, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Maynadie M et al (2011) Survival of European patients diagnosed with lymphoid neoplasms in 2000–2002: results of the HAEMACARE project. Haematologica 96:720–728. doi: 10.3324/haematol.2010.034264 PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O et al (2010) Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116:3724–3734. doi: 10.1182/blood-2010-05-282632 CrossRefPubMedGoogle Scholar
  24. 24.
    De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D et al (2014) Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol 15:23–34. doi: 10.1016/s1470-2045(13)70546-1 CrossRefPubMedGoogle Scholar
  25. 25.
    Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J et al (2014) Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study. Lancet Oncol 15:35–47. doi: 10.1016/s1470-2045(13)70548-5 CrossRefPubMedGoogle Scholar
  26. 26.
    Svendsen AL, Feychting M, Klaeboe L, Langmark F, Schuz J (2007) Time trends in the incidence of acute lymphoblastic leukemia among children 1976–2002: a population-based Nordic study. J Pediatr 151:548–550. doi: 10.1016/j.jpeds.2007.07.006 CrossRefPubMedGoogle Scholar
  27. 27.
    Coebergh JW, Reedijk AM, de Vries E, Martos C, Jakab Z, Steliarova-Foucher E et al (2006) Leukaemia incidence and survival in children and adolescents in Europe during 1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 42:2019–2036. doi: 10.1016/j.ejca.2006.06.005 CrossRefPubMedGoogle Scholar
  28. 28.
    Fajardo-Gutierrez A, Juarez-Ocana S, Gonzalez-Miranda G, Palma-Padilla V, Carreon-Cruz R, Ortega-Alvarez MC et al (2007) Incidence of cancer in children residing in ten jurisdictions of the Mexican Republic: importance of the Cancer registry (a population-based study). BMC Cancer 7:68. doi: 10.1186/1471-2407-7-68 PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL (2005) A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur J Cancer Care (Engl) 14:53–62. doi: 10.1111/j.1365-2354.2005.00513.x CrossRefGoogle Scholar
  30. 30.
    Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kholer B, Piñeros M et al (2013) Cancer Incidence in Five Continents Volume X (IARC Scientific Publications No. 164). Lyon, IARCGoogle Scholar
  31. 31.
    Ahmad OB, Boschi-Pinto C, López AD, Murray CJLLR, Inoue M (2001) Age standardization of rates: a new WHO standard. World Health Organization, GenevaGoogle Scholar
  32. 32.
    United Nations, Department of Economic and Social Affairs, Population Division (2013) World Population Prospects: The 2012 Revision. Accessed Feb 21, 2014
  33. 33.
    Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P et al (2013) Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica 98:1702–1710. doi: 10.3324/haematol.2012.080432 PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Toft N, Schmiegelow K, Klausen TW, Birgens H (2012) Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998–2008. Br J Haematol 157:97–104. doi: 10.1111/j.1365-2141.2011.09020.x CrossRefPubMedGoogle Scholar
  35. 35.
    Li X, Li J, Hu Y, Xie W, Du W, Liu W et al (2012) A comprehensive cytogenetic classification of 1466 Chinese patients with de novo acute lymphoblastic leukemia. Leuk Res 36:720–726. doi: 10.1016/j.leukres.2011.12.016 CrossRefPubMedGoogle Scholar
  36. 36.
    Chen B, Wang YY, Shen Y, Zhang WN, He HY, Zhu YM et al (2012) Newly diagnosed acute lymphoblastic leukemia in China (I): abnormal genetic patterns in 1346 childhood and adult cases and their comparison with the reports from Western countries. Leukemia 26:1608–1616. doi: 10.1038/leu.2012.26 CrossRefPubMedGoogle Scholar
  37. 37.
    Dugas M, Messerer D, Hasford J, Haferlach T, Heinze B, Ludwig W et al (2003) German multicenter study group for adult ALL (GMALL): recruitment in comparison to ALL incidence and its impact on study results. Ann Hematol 82:83–87. doi: 10.1007/s00277-002-0585-x PubMedGoogle Scholar
  38. 38.
    Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M et al (2007) Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 109:3189–3197. doi: 10.1182/blood-2006-10-051912 CrossRefPubMedGoogle Scholar
  39. 39.
    Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T et al (2007) Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 21:1907–1914. doi: 10.1038/sj.leu.2404824 CrossRefPubMedGoogle Scholar
  40. 40.
    Kantarjian H, Thomas D, O’Brien S, Cortes J, Giles F, Jeha S et al (2004) Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101:2788–2801. doi: 10.1002/cncr.20668 CrossRefPubMedGoogle Scholar
  41. 41.
    Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Database: Incidence—SEER 18 Regs Research Data + Hurrican Katrina Impacted louisiana Cases, Nov 2013 Sub (1973–2011 varying)—Linked to County Attributes—Total U.S., 1969–2012 Counties, National Cancer Instisute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014 (updated 5/7/2017), based on the November 2013 submission
  42. 42.
    Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Database: Mortality—All COD, Aggregated With State, Total U.S. (1969–2010) <Katrina/Rita Population Adjustment>, National Cancer Instisute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013. Underlying mortality data provided by NCHS (
  43. 43.
    World Health Organization (2013) Global Health Observatory Data Repository. Accessed May 19, 2014
  44. 44.
    Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP (2005) Years of life lost (YLL) from cancer is an important measure of population burden—and should be considered when allocating research funds. Br J Cancer 92:241–245. doi: 10.1038/sj.bjc.6602321 PubMedCentralPubMedGoogle Scholar
  45. 45.
    Office for National Statistics (2015) Causes of Death. Accessed Jan 8, 2015
  46. 46.
    NHS National Services Scotland, Information Services Division (2015) Data tables: cancer mortality by year. Accessed Jan 8, 2015
  47. 47.
    Instituto Nacional de Estadística (2015) Health: Deaths statistic according to cause of death. Accessed Jan 8, 2015
  48. 48.
    Australian Institute of Health and Welfare (AIHW) (2014) Australian Cancer Incidence and Mortality (ACIM) books: acute lymphoblastic leukemia. AIHW, Canberra. Accessed Jan 8, 2015
  49. 49.
    Ehngholm G, Ferlay J, Christensen N, Kejs AMT, Johannesen TB, Khan S, et al (2014) NORDCAN: Cancer incidence, mortality, prevalence and survival in the Nordic countries, version 7.0. Association of the Nordic Cancer Registries. Danish Cancer Society. Accessed Jan 8, 2015
  50. 50.
    Linet MS, Dores GM, Kim CJ, Devesa SS, Morton LM (2013) Epidemiology and hereditary aspects of acute leukemia. In: Wiernik PH, Goldman JM, Dutcher J (eds) Neoplastic diseases of the blood, 5th edn. Springer, New York, pp 199–212CrossRefGoogle Scholar
  51. 51.
    Perez-Saldivar ML, Fajardo-Gutierrez A, Bernaldez-Rios R, Martinez-Avalos A, Medina-Sanson A, Espinosa-Hernandez L et al (2011) Childhood acute leukemias are frequent in Mexico City: descriptive epidemiology. BMC Cancer 11:355. doi: 10.1186/1471-2407-11-355 PubMedCentralCrossRefPubMedGoogle Scholar
  52. 52.
    Novak I, Jaksic O, Kulis T, Batinjan K, Znaor A (2012) Incidence and mortality trends of leukemia and lymphoma in Croatia, 1988–2009. Croat Med J 53:115–123PubMedCentralCrossRefPubMedGoogle Scholar
  53. 53.
    Hjalgrim LL, Rostgaard K, Schmiegelow K, Soderhall S, Kolmannskog S, Vettenranta K et al (2003) Age- and sex-specific incidence of childhood leukemia by immunophenotype in the Nordic countries. J Natl Cancer Inst 95:1539–1544CrossRefPubMedGoogle Scholar
  54. 54.
    Rowe JM (2010) Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol 150:389–405. doi: 10.1111/j.1365-2141.2010.08246.x PubMedGoogle Scholar
  55. 55.
    Faderl S, O’Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D et al (2010) Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 116:1165–1176. doi: 10.1002/cncr.24862 CrossRefPubMedGoogle Scholar
  56. 56.
    Ludwig H, Bolejack V, Crowley J, Blade J, Miguel JS, Kyle RA et al (2010) Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 28:1599–1605. doi: 10.1200/jco.2009.25.2114 CrossRefPubMedGoogle Scholar
  57. 57.
    Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B et al (2014) Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol 15:931–942. doi: 10.1016/s1470-2045(14)70282-7 CrossRefPubMedGoogle Scholar
  58. 58.
    Horibe K, Saito AM, Takimoto T, Tsuchida M, Manabe A, Shima M et al (2013) Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006–2010): based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol 98:74–88. doi: 10.1007/s12185-013-1364-2 CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Aaron J. Katz
    • 1
    Email author
  • Victoria M. Chia
    • 1
  • Wilma M. Schoonen
    • 2
  • Michael A. Kelsh
    • 1
  1. 1.Center for Observational ResearchAmgen Inc.Thousand OaksUSA
  2. 2.Center for Observational ResearchAmgen Ltd.UxbridgeUK

Personalised recommendations